Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
55.06
-5.54 (-9.14%)
At close: Nov 13, 2024, 4:00 PM
55.73
+0.67 (1.22%)
After-hours: Nov 13, 2024, 7:53 PM EST

Company Description

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.

The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics, Inc.
Viking Therapeutics logo
Country United States
Founded 2012
IPO Date Apr 29, 2015
Industry Biotechnology
Sector Healthcare
Employees 27
CEO Brian Lian

Contact Details

Address:
9920 Pacific Heights Boulevard, Suite 350
San Diego, California 92121
United States
Phone 858 704 4660
Website vikingtherapeutics.com

Stock Details

Ticker Symbol VKTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001607678
CUSIP Number 92686J106
ISIN Number US92686J1060
Employer ID 46-1073877
SIC Code 2834

Key Executives

Name Position
Dr. Brian Lian Ph.D. President, Chief Executive Officer and Director
Gregory S. Zante Chief Financial Officer
Marianne Mancini Chief Operating Officer
Michael Morneau Vice President of Finance and Administration
Dr. Geoffrey E. Barker Ph.D. Senior Vice President of Pharmaceutical Development

Latest SEC Filings

Date Type Title
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 144 Filing
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 4, 2024 8-K Current Report
Oct 28, 2024 144 Filing
Oct 25, 2024 144 Filing
Oct 25, 2024 144 Filing
Oct 23, 2024 10-Q Quarterly Report
Oct 23, 2024 8-K Current Report
Oct 18, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals